Bioequivalence and the immunogenicity of biopharmaceuticals

Nature Reviews Drug Discovery

Volumn 1, Issue 6, 2002, Pages 457-462

  Schellekens, Huub ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ALPHA INTERFERON; ALPHA2A INTERFERON; AMINO ACID; BETA INTERFERON; BLOOD CLOTTING FACTOR 8; CALCITONIN; CHORIONIC GONADOTROPIN; DENILEUKIN DIFTITOX; DEOXYRIBONUCLEASE; EPITOPE; ERYTHROPOIETIN; GENERIC DRUG; GONADORELIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; GROWTH HORMONE; HLA ANTIGEN; HUMAN SERUM ALBUMIN; IMMUNOLOGICAL ADJUVANT; INSULIN; INTERLEUKIN 2; INTERLEUKIN 3; RECOMBINANT BETA INTERFERON; RECOMBINANT DNA; SALCATONIN; STAPHYLOKINASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR DERIVATIVE; UNINDEXED DRUG; BIOLOGICAL PRODUCT;

AMINO ACID SEQUENCE; BIOASSAY; BIOEQUIVALENCE; DRUG CONTAMINATION; DRUG EFFICACY; DRUG FORMULATION; DRUG IMPURITY; DRUG MANUFACTURE; DRUG MARKETING; DRUG STORAGE; GENE EXPRESSION; GLYCOSYLATION; HOST CELL; HUMAN; IMMUNOGENICITY; IMMUNOREACTIVITY; METHODOLOGY; NONHUMAN; PATENT; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; SURFACE PLASMON RESONANCE; ANIMAL; ANIMAL MODEL; ANTIBODY PRODUCTION; IMMUNOLOGY; PHARMACOKINETICS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; BIOLOGICAL PRODUCTS; GLYCOSYLATION; HUMANS; MODELS, ANIMAL; THERAPEUTIC EQUIVALENCY;

EID: 0036598634     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd818     Document Type: Review

References (67)

1. Chance, R. E., Root, M. A. & Galloway, J. A. The immunogenicity, of insulin preparations. Acta Endocrinol. Suppl. 205, 185-198 (1976).
2. Milner, R. D. G. & Fiodh, H. (eds) Immunological Aspects of Human Growth Hormone: Proceedings of a Workshop, London, 12 November 1985. (Medical Education Services, Oxford, 1986).
3. Jacquemin, M. G. & Saint-Remy, J. M. Factor VIII immunogenicity. Haemophilia 4, 552-557 (1998).
4. Dietrich, F. M., Fischer, J. A. & Bijvoet, O. L. Formation of antibodies to synthetic human calcitonin during treatment of Paget's disease. Acta Endocrinol. 92, 468-476 (1979).
5. Schernthaner, G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 16, 155-165 (1993).
6. Rosenschein, U., Lenz, R., Radnay, J., Ben Tovim, T. & Rozenszajn, L. A. Streptokinase immunogenicity in thrombolytic therapy for acute myocardial infarction. Isr. J. Med. Sci. 27, 541-545 (1991).
7. Vanderschueren, S. M., Stassen, J. M. & Collen, D. On the immunogenicity of recombinant staphylokinase in patients and in animal models. Thromb. Haemost. 72, 297-301 (1994).
8. Chaffee, S. et al. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J. Clin. Invest. 89, 1643-1651 (1992).
9. Grauer, A., Frank-Raue, K., Schroth, J., Raue, F. & Ziegler, R. Neutralizing antibodies against salmon calcitonin. The cause of a treatment failure in Paget's disease. Dtsch. Med. Wochenschr. 119, 507-510 (1994).
10. Gilles, J. G., Jacquemin, M. G. & Saint-Remy, J. M. Factor VIII inhibitors. Thromb. Haemost. 78, 641-646 (1997).
11. Frasier, S. D. Human pituitary growth hormone (hGH) therapy in growth hormone deficiency. Endocr. Rev. 4, 155-170 (1983).
12. Dummer, R. et al. Formation of neutralizing antibodies against natural interferon-β, but not against recombinant interferon-γ during adjuvant therapy for high-risk malignant melanoma patients. Cancer 67, 2300-2304 (1991).
13. Prabhakar, S. S. & Muhlfelder, T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin. Nephrology 47, 331-335 (1997).
14. Oberg, K. et al. Treatment of malignant carcinoid tumors with recombinant interferon-α2B: development of neutralizing interferon antibodies and possible loss of antitumor activity. J. Natl Cancer Inst. 81, 531-535 (1989).
15. Zang, Y. C. et al. Immunoregulation and blocking antibodies induced by interferon-β treatment in MS. Neurology 55, 397-404 (2000).
16. Kontsek, P., Liptakova, H. & Kontsekova, E. Immunogenicity of interferon-α2 in therapy: structural and physiological aspects. Acta Virol. 43, 63-70 (1999).
17. Melian, E. B. & Plosker, G. L. Interferon αcon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs 61, 1661-1691 (2001).
18. Girard, F. & Gourmelen, M. Clinical experience with somatonorm. Acta Pœdiatr. Scand. 325, 29-32 (1986).
19. Gribben, J. G. et al. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 335, 434-437 (1990).
20. Karpusas, M. et al. The structure of human interferon-β: implications for activity. Cell. Mol. Life Sci. 54, 1203-1216 (1998).
21. MacDougall, I. C. Novel erythropoiesis stimulating protein. Semin. Nephrology 20, 375-381 (2000).
22. Antonelli, G. et al. Interferon antibodies in patients with Infectious diseases. Biotherapy 10, 7-14 (1997).
23. Prümmer, O. Treatment-induced antibodies to interleukin-2. Biotherapy 10, 15-24 (1997).
24. Stubbe, P. in Growth Hormone Deficiency. Proceedings of a Workshop in Tubingen, 1981 (eds Ranke, M. B. & Bierich, J. R.) 92-99 (Urban and Schwarzenberg, Munich, 1983).
25. Fierlbeck, G. et al. Neutralizing interferon-β antibodies in melanoma patients treated with recombinant and natural interferon-β. Cancer Immunol. Immunother. 39, 263-268 (1994).
26. Hochuli, E. Interferon immunogenicity: technical evaluation of interferon-α2A. J. Int. Cytokine Res. 17, S15-S21 (1997).
27. Moore, W. V. & Leppert, P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J. Clin. Endocrinol. Metab. 51, 691-697 (1980).
28. Ryff, J.-C. Clinical investigation of the immunogenicity of interferon-α2A. J. Int. Cytokine Res. 17, S29-S33 (1997).
29. Rosendaal F. R. et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood 81, 2180-2186 (1993).
30. Cleland, J. L., Powell, M. F. & Shire, S. J. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carrier Syst. 10, 307-377 (1993).
31. Palleroni, A. V. et al. Interferon immunogenicity: preclinical evaluation of interferon-α2A. J. Int. Cytokine Res. 17, S23-S27 (1997).
32. Perini, P. et al. Interferon-β (IFN-β) antibodies in interferon-β1A- and interferon-β1B-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-β immunogenicity in vivo. Eur. Cytokine Netw. 12, 56-61 (2001).
33. Kirchner, H. et al. Subcutaneous interleukin-2 and interferon-α2B in patients with metastatic renal cell cancer: the German outpatient experience. Mol. Biother. 2, 145-154 (1990).
34. Levy, F., Muff, R., Dotti-Sigrist, S., Dambacher, M. A. & Fischer, J. A. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease. J. Clin. Endocrinol. Metab. 67, 541-545 (1988).
35. Eisenberg, J. D. et al. Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. J. Pediatr. 131, 118-124 (1997).
36. Ross, C. et al. Immunogenicity of interferon-β in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann. Neurol. 48, 706-712 (2000).
37. Antonelli G. In vivo development of antibodies to interferon: an update to 1996. J. Int. Cytokine Res. 17, S39-S46 (1997).
38. Prescott, R. et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Blood 89, 3663-3671 (1997).
39. Fakharzadeh, S. S. & Kazazian, H. H. Jr. Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin. Thromb. Hemost. 26, 167-171 (2000).
40. Schernthaner, G. et al. Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals. Diabetes Care 6, 43-48 (1983).
41. Jeandidier, N. et al. Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices. Diabetologia 38, 577-584 (1995).
42. Schellekens, H., Ryff, J.-C. & van der Meide, P. H. Assays for antibodies to human interferon-α: the need for standardisation. J. Int. Cytokine Res. 17, 5-8 (1997).
43. Casadevall, N. et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346, 460-475 (2002).
44. Wang, B. S. et al. Augmentation of hormonal activities with antibodies from cattle immunized with a combination of synthetic and recombinant growth hormone peptide. Anim. Biotechnol. 9, 21-33 (1998).
45. Zipkin, I. Amgen lays MGDF to rest. BioCentury [online] (cited 29 Apr 02) (1998).
46. Chan, S. H. et al. Engineering of a mini-trichosanthin that has lower antigenicity by deleting its C-terminal amino acid residues. Biochem. Biophys. Res. Commun. 270, 279-285 (2000).
47. Collen, D. et al. Recombinant staphylokinase variants with altered immunoreactivity. I. Construction and characterization. Circulation 94, 197-206 (1996).
48. Chang, T. Y. Towards a quantitative model of immunogenicity: counting pathways in sequence space. J. Theor. Biol. 206, 255-278 (2000).
49. Van Regenmortel, M. H. Analysing structure-function relationships with biosensors. Cell. Mol. Life Sci. 58, 794-800 (2001).
50. Vanderschueren, S. M., Stassen, J. M. & Colen, D. On the immunogenicity of recombinant staphylokinase in patients and in animal models. Thromb. Haemost. 72, 297-301 (1994).
51. Collen, D., De Cock, F. & Stassen, J. M. Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons. Circulation 87, 996-1006 (1993).
52. Dempster, A. M. Nonclinical safety evaluation of biotechnologicaly derived pharmaceuticals. Biotechnol. Annu. Rev. 5, 221-258 (2000).
53. Randolph, J. F., Stokol, T., Scarlett, J. M. & MacLeod, J. N. Comparison of biological activity and safety of recombinant canine erythropoietin with that of recombinant human erythropoietin in clinically normal dogs. Am. J. Vet. Res. 60, 636-642 (1999).
54. Zwickl, C. M. et al. Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys. Fundam. Appl. Toxicol. 16, 275-287 (1991).
55. Wierda, D., Smith, H. W. & Zwickl, C. M. Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology 158, 71-74 (2001).
56. Ottesen, J. L. et al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 37, 1178-1185 (1994).
57. Stewart, T. A. et al. Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis. Mol. Biol. Med. 6, 275-281 (1989).
58. Palleroni, A. V. et al. Interferon immunogenicity: preclinical evaluation of interferon-α2A. J. Int Cytokine Res. 17, S23-S27 (1997).
59. Du, X. & Tang, J. G. Effects of deleting A19 tyrosine from insulin. Biochem. Mol. Biol. Int. 44, 507-513 (1998).
60. Steis, R. G. et al. Loss of interferon antibodies during prolonged continuous interferon-α2A therapy in hairy cell leukemia. Blood 77, 792-798 (1991).
61. Roffi, L. et al. Breakthrough during recombinant interferon-α therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology 21, 645-649 (1995).
62. Schellekens, H. & Ryff, J.-C. Biogenerics; the Off-Patent Biotech Products. Trends Pharmacol. Sci. 23, 119-121 (2002).
63. Chaffee, S. et al. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J. Clin. Invest 89, 1643-1651 (1992).
64. Blumenfeld, Z., Frisch, L. & Conn, P. M. Gonadotropin-releasing hormone (GnRH) antibodies formation in hypogonadotropic azoospermic men treated with pulsatile GnRH-diagnosis and possible alternative treatment, Fertil. Steril. 50, 622-629 (1988).
65. Olsen, E. et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 19, 376-388 (2001).
66. Claustrat, B., David, L., Faure, A. & Francois, R. Development of anti-human chorionic gonadotropin antibodies in patients with hypogonadotropic hypogonadism. A study of four patients. J. Clin. Endocrinol. Metab. 57, 1041-1047 (1983).
67. Ragnhammar, P. & Wadhwa, M. Neutralising antibodies to granulocyte-macrophage colony stimulating factor(GM-CSF) in carcinoma patients following GM-CSF combination therapy. Med. Oncol. 13, 161-166 (1996).